Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep apnea treatment may cut heart ablation need in AFib patients

NCT ID NCT04606693

Disease control Sponsor: Hospital San Carlos, Madrid Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether screening for and treating sleep apnea can reduce the burden of atrial fibrillation (AFib) in patients who are candidates for heart ablation. Fifty adults with paroxysmal or persistent AFib that hasn't responded to medication will be screened for sleep apnea. Those diagnosed will receive standard treatment (like CPAP or lifestyle changes) and be monitored for three months. The goal is to see if their AFib improves enough to avoid the need for ablation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CPAP and lifestyle measures for sleep apnea
What this could lead to
If successful, this could show that treating sleep apnea helps control atrial fibrillation, potentially reducing the need for heart ablation in some patients.
What could go wrong
This is a small, non-randomized study with only 50 participants, so results may not apply broadly. It is also early-stage and observational, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with paroxysmal or persistent atrial fibrillation * Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic * No previous diagnosis of apnea-hypopnea syndrome Exclusion Criteria: * Patients \<18 years * Pregnant women * Doubts about the patient's ability to perform a home respiratory polygraphy * Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required) * Unavailability for follow-up at our center for at least 1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Apnea syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Apnea atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Apnea syndrome Atrial fibrillation (paroxysmal) Atrial fibrillation, persistent Hypopnea syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Clínico San Carlos

    RECRUITING

    Madrid, Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.